News zum Sektor Gesundheit aus Indien

 

Um den gesamten Artikel unter timesofindia.indiatimes.com zu lesen, klicken Sie bitte auf die Überschrift...

Manipal Health Enterprises Pvt., which runs the Manipal Hospitals chain, is likely to launch its initial public offering as early as next month, according to people familiar with the matter....

Indian drugmaker Biocon Ltd. is aiming to become the world's top supplier of insulin in the coming years, its co-founder Kiran Mazumdar-Shaw said, by capturing growing demand for the critical drug while Big Pharma shifts its focus to other medicines....

Carlyle Group Inc. has invited pitches from investment banks to advise on a potential India initial public offering of its recently acquired healthcare billing service business, according to people familiar with the matter....

State Bank of India plans to join a group of global lenders in funding Sun Pharmaceutical Industries Ltd.'s $12 billion overseas acquisition, according to people familiar with the matter....

Customs records show millions of dollars' worth of the high-strength synthetic opioid being shipped from India every month to Nigeria, Sierra Leone and Ghana....

Biocon CEO, Shreehas Tambe, discusses their push into the generic GLP-1 market, after Novo Nordisk cut prices of its blockbuster weight-loss and diabetes medications in India. He also spoke about the company's latest set of earnings on Insight with Haslinda Amin. (Source: Bloomberg)...

Swiss pharma major Novartis is sharpening its strategy in India as a pure-play innovator across core therapy segments, including cardiovascular, oncology, and immunology. The company is moving further up the value chain in India, with early scientific discovery and Phase I studies beginning to take shape....

Novo Nordisk A/S saw a 40% surge in sales of its diabetes and weight-loss drugs in India last month, after steep price cuts boosted demand for its branded treatments even as generic GLP-1 therapies flood the market....

For Indian billionaire Dilip Shanghvi, who made his fortune selling cheap generic drugs to the world, it was clear at least more than a decade ago that a shift toward specialty treatments would be key to success in the crowded local market....

Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

To fuel its global ambitions, Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion....

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter timesofindia.indiatimes.com zu lesen, klicken Sie bitte auf die Überschrift...

Quadria Capital-backed Maxivision Eye Hospitals Pvt. has begun preparations for an initial public offering, according to people familiar with the matter, as India's healthcare services sector continues to draw investor interest....

Eli Lilly loses share in India's GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price cuts to defend Ozempic, Wegovy....

The flood of cheap copies of Novo Nordisk A/S' blockbuster drug semaglutide in India is already reshaping the country's fast-growing obesity market, cutting into Eli Lilly & Co.'s early lead and offering a first real test of how Novo may fare as its patents expire worldwide....

India's pharmaceutical exports are thriving, reaching $28.29 billion in April-February FY26, a 5.6% rise despite global challenges. The sector, currently valued at $60 billion, is projected to hit $130 billion by 2030. Leaders are optimistic about continued growth, even with potential US tariff impacts on future exports....

The US has imposed up to 100% tariffs on patented drugs and certain metals, aiming to boost domestic manufacturing. While India's generic drug exports are largely exempt, firms producing branded medicines or inputs for patented drugs may face pressure. Developed nations are expected to bear the brunt of these new measures....